Tag: high-risk multiple myeloma

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Biologic teclistamab shows promise in treatment of refractory multiple myeloma in phase 1 drug study

byJessie Willisand1 others

September 8, 2021

1. Patients on the recommended phase 2 dosage of teclistamab had no dose-limiting adverse events. 2. There was a 65% ...

$The STORM trial: treatment refractory multiple myeloma patients experience response with selinexor$

Isatuximab improves progression-free survival in patients receiving carfilzomib–dexamethasone treatment for multiple myeloma

byAlice Wangand1 others

July 1, 2021

1. Higher rates of treatment response were observed in patients receiving isatuximab with carfilzomib–dexamethasone than carfilzomib–dexamethasone alone. 2. Improved median ...

$#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma$

#VisualAbstract Idecabtagene vicleucel demonstrates higher efficacy over currently available therapies in triple-class relapsed and refractory multiple myeloma

byKathleen Lau

July 1, 2021

#VisualAbstract SWOG-1211: Addition of elotuzumab to RVd induction and maintenance (lenalidomide, bortezomib, dexamethasone) did not improve patient outcomes in untreated, high-risk multiple myeloma

byKathleen Lau

January 14, 2021

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

No Result

View All Result